REG - Zoetic Interntnl PLC - Issue of Equity

Chill BrandsAnnouncement

08/11/2019 09:05

RNS Number : 7834S
Zoetic International PLC
08 November 2019
 


 
8 November 2019
 
Zoetic International plc
("Zoetic International" or the "Company")
 
Issue of shares
 
Zoetic International, the London listed vertically integrated CBD and natural resources company, announces that, pursuant to the exercise of warrants, an application has been made for an additional 790,000 ordinary shares in the Company ("New Ordinary Shares") to be admitted to trading on the Official List of the UK Listing Authority by way of a Standard Listing and to trading on the London Stock Exchange's Main Market for listed securities ("Admission"). Admission is expected to take place on 14 November 2019.
 
Following Admission, the New Ordinary Shares will rank pari passu in all respects with the existing ordinary shares of 1 pence each in issue, including the right to receive all dividends and other distributions declared, and the total number of ordinary shares in Zoetic International with voting rights will be 148,910,034. This figure may be used by Zoetic International shareholders as the denominator for calculations to determine if they have a notifiable interest in Zoetic International under the Disclosure and Transparency Rules, or if such interest has changed.
 
**ENDS**
 
Enquiries
 
Zoetic International plc                                                                                               +44 (0) 1738 472 029
Nick Tulloch
 
IFC Advisory Ltd                                                                                                            +44 (0) 20 3934 6630
Tim Metcalfe
Graham Herring
Florence Chandler
               
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOEVVLBBKFFEFBK